The effect of treatment at minority-serving hospitals on outcomes for bladder cancer
Healthcare for racial minorities is densely concentrated at a small subset of hospitals in the United States. Understanding long-term outcomes at these minority-serving hospitals is highly relevant to elucidating the sources of racial disparities in cancer care. We investigated the effect of treatment at a minority-serving hospital on overall survival and receipt of definitive treatment for bladder cancer. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 14, 2018 Category: Urology & Nephrology Authors: Sean A. Fletcher, Philipp Gild, Alexander P. Cole, Malte W. Vetterlein, Adam S. Kibel, Toni K. Choueiri, Guru P. Sonpavde, Mark A. Preston, Daniel Pucheril, Mani Menon, Maxine Sun, Stuart R. Lipsitz, Quoc-Dien Trinh Tags: Original article Source Type: research

Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer
Several new compounds are now available for castration resistant prostate cancer (CRPC). Individual costs range between $40,000 and $93,000 with mean survival extensions from 2.4 to 4.8 months. Currently, it remains unclear how patients with prostate cancer (PCa) value the effect of these therapies in the setting of CRPC. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 14, 2018 Category: Urology & Nephrology Authors: Tarik Benidir, Karen Hersey, Antonio Finelli, Rob Hamilton, Anthony M. Joshua, Girish Kulkarni, Alexandre Zlotta, Neil Fleshner Tags: Original article Source Type: research

First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database
To analyze factors associated with metastases, prostate cancer-specific mortality, and all-cause mortality in pN1 patients. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 8, 2018 Category: Urology & Nephrology Authors: Michelle L. McDonald, Lauren E. Howard, William J. Aronson, Martha K. Terris, Matthew R. Cooperberg, Christopher L. Amling, Stephen J. Freedland, Christopher J. Kane Tags: Original article Source Type: research

Metabolic syndrome is not associated with greater evidences of proliferative inflammatory atrophy and inflammation in patients with suspected prostate cancer
To evaluate the association between metabolic syndrome (MetS) and proliferative inflammatory atrophy (PIA) in patients with suspected prostate cancer (PCa). (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 8, 2018 Category: Urology & Nephrology Authors: Giorgio I. Russo, Sebastiano Cimino, Giorgia Giranio, Federica Regis, Vincenzo Favilla, Salvatore Privitera, Fabio Motta, Rosario Caltabiano, Arnulf Stenzl, Tilman Todenh öfer, Giuseppe Morgia Tags: Original article Source Type: research

Role of immunotherapy in bacillus Calmette –Guérin-unresponsive non–muscle invasive bladder cancer
Intravesical instillation of live attenuated bacillus Calmette –Guérin (BCG) is the gold standard for patients with intermediate- and high-risk non–muscle-invasive bladder cancer (NMIBC). BCG-failures include a heterogenous population of patients who share a designation of disease recurrence or progression following BCG and include patients with complete u nresponsiveness to BCG, patients who respond initially but develop relapse and, in some cases, patients who are intolerant to BCG due to side effects. (Source: Urologic Oncology: Seminars and Original Investigations)
Source: Urologic Oncology: Seminars and Original Investigations - February 8, 2018 Category: Urology & Nephrology Authors: Neelam Mukherjee, Robert S. Svatek, Ahmed M. Mansour Tags: Review article Source Type: research